Sunosi

Drug Overview

In the field of Neurology, managing profound, debilitating daytime sleepiness is a complex challenge. Conditions like narcolepsy or severe sleep apnea cause the brain to struggle to maintain sustained wakefulness during the day. Historically, doctors relied heavily on older amphetamine-based stimulants, which often cause severe heart strain, high blood pressure, and carry a high risk of addiction.

Sunosi acts as a highly effective Targeted Therapy to promote wakefulness without forcefully squeezing the brain’s chemicals as traditional stimulants do. It belongs to a newer Drug Class known as Dopamine and Norepinephrine Reuptake Inhibitors (DNRIs). Because this “Smart Drug” is eliminated from the body almost entirely (95%) unchanged through the urine, neurologists must work closely with a patient’s kidney doctor (nephrologist) to strictly adjust the dose for anyone with Chronic Kidney Disease (CKD) to prevent the medicine from building up to toxic levels.

• Generic Name: Solriamfetol
• US Brand Names: Sunosi
• Drug Class: Dopamine and Norepinephrine Reuptake Inhibitor (DNRI); Wake-Promoting Agent
• Route of Administration: Oral (Tablet)
• FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

Sunosi is classified as a “Smart Drug” because it modifies how the brain manages its natural chemical messengers, rather than simply flooding the brain with artificial stimulation.

At the molecular level, Sunosi targets the specific neural pathways responsible for alertness and attention:

1. The Brain’s Natural Signals: Nerve cells in the brain use two specific chemicals dopamine and norepinephrine to signal alertness, focus, and wakefulness.
2. The Recycling Pumps: Normally, after these chemicals send their “stay awake” message, they are quickly vacuumed back up (recycled) into the nerve cell by specific pumps known as the Dopamine Transporter (DAT) and Norepinephrine Transporter (NET).
3. Blocking the Pumps (Inhibition of Reuptake): Solriamfetol binds directly to these DAT and NET pumps, effectively blocking them from working.
4. Increasing Chemical Signals: By preventing the recycling process, Sunosi forces dopamine and norepinephrine to remain in the space between nerve cells (the synaptic cleft) for a much longer time. This buildup amplifies and prolongs the brain’s natural wakefulness signals, keeping the patient alert throughout the day.

FDA-Approved Clinical Indications

Sunosi is officially approved to treat excessive daytime sleepiness caused by specific neurological and respiratory conditions.

• Oncological Uses:
  • There are currently no FDA-approved oncological (cancer-related) uses for this medication.
• Non-Oncological Uses:
  • Narcolepsy: Treatment to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
  • Obstructive Sleep Apnea (OSA): Treatment to improve wakefulness in adult patients with EDS associated with OSA.
  • (Important Note for OSA Patients: Sunosi is an add-on therapy. It keeps you awake during the day, but it does NOT treat the underlying airway obstruction at night. Patients must continue using their CPAP machines while taking this medication).

Dosage and Administration Protocols

Sunosi is taken orally once daily immediately upon waking up. It can be taken with or without food. Because of its long-lasting effects, it should never be taken within 9 hours of your planned bedtime to prevent severe insomnia.

Dose Adjustments for Insufficiency:

Because Sunosi is cleared directly by the kidneys, the dosage must be strictly adjusted based on the patient’s estimated Glomerular Filtration Rate (eGFR) to prevent a toxic, heart-racing buildup in the blood:

• Mild Kidney Impairment (eGFR 60-89 mL/min): No dose adjustment is needed.
• Moderate Kidney Impairment (eGFR 30-59 mL/min): Starting dose is 37.5 mg once daily. The maximum allowed dose is strictly capped at 75 mg once daily.
• Severe Kidney Impairment (eGFR 15-29 mL/min): Starting dose is 37.5 mg taken once every other day. The maximum allowed dose is strictly capped at 37.5 mg once daily.
• End-Stage Renal Disease (ESRD) (eGFR < 15 mL/min): Use is completely forbidden (contraindicated). It must not be used in patients undergoing hemodialysis.

Clinical Efficacy and Research Results

Recent clinical registry data and multi-center neurology trials (2020–2026) strongly validate the efficacy of solriamfetol as a first-line agent for managing excessive daytime sleepiness.

• Improvement in Wakefulness: In the standard “Maintenance of Wakefulness Test” (MWT), patients taking optimal doses of Sunosi demonstrated a clinically significant increase in their ability to stay awake in a dark, quiet room. Patients experienced an average increase of 10 to 12 minutes in sustained wakefulness compared to those taking a placebo.
• Reduction in Sleepiness: Patients show marked improvement on the Epworth Sleepiness Scale (ESS), typically registering a 4.5 to 6.5 point drop. This indicates a massive reduction in the overwhelming, dangerous urge to sleep during daytime activities like driving or working.
• Blood Pressure and Nephrology Considerations: Clinical data reveal that Sunosi causes a dose-dependent increase in systemic blood pressure (an average increase of 1 to 2 mmHg) and resting heart rate. For neurologists and nephrologists managing patients with CKD where controlling hypertension is vital to slowing kidney failure this requires careful monitoring and potential adjustment of the patient’s daily blood pressure medications.

Safety Profile and Side Effects

Black Box Warning:

None. (Sunosi does not carry an FDA Black Box Warning. However, it is a Schedule IV controlled substance due to a low risk of abuse and chemical dependence.)

Common Side Effects (>10%)

• Headache: Mild to moderate head pain.
• Nausea: Upset stomach or noticeably decreased appetite.
• Insomnia: Trouble falling asleep at night (especially if the pill is taken too late in the morning).
• Anxiety: Feeling “jittery,” nervous, or on edge.
• Dry Mouth: A lack of saliva.

Serious Adverse Events

• Elevated Blood Pressure and Heart Rate: Can increase the risk of cardiovascular events, strokes, or accelerated kidney damage in vulnerable populations if not monitored closely.
• Psychiatric Symptoms: Can cause or severely worsen underlying anxiety, irritability, and agitation. In rare cases, it can trigger manic episodes or hallucinations (seeing things that are not there).
• Severe Hypersensitivity: Rare allergic reactions, including rash, hives, or dangerous swelling of the face and throat.

Management Strategies

• Cardiovascular Monitoring: Blood pressure and heart rate must be checked by a doctor before starting the drug, and monitored regularly at home during treatment. If hypertension worsens, the Sunosi dose must be reduced or the drug stopped.
• Psychiatric Care: If a patient develops sudden, severe mood changes, explosive irritability, or begins having hallucinations, the medication should be stopped and a physician notified immediately.

Research Areas

In the evolving field of neuro-nephrology (2022–2026), managing the profound, debilitating fatigue associated with Chronic Kidney Disease and comorbid sleep apnea is a major clinical hurdle. While Sunosi is a Targeted Therapy specifically for daytime sleepiness, ongoing clinical research is investigating the broader systemic benefits of keeping patients awake and active.

Chronic low oxygen from untreated sleep apnea and severe daytime inactivity both heavily contribute to cellular oxidative stress and kidney tissue damage. Researchers are currently evaluating whether using “Smart Drugs” like Sunosi to restore normal daytime activity levels and encourage better CPAP compliance at night indirectly improves overall cardiovascular health and supports the body’s natural cellular repair mechanisms in moderate CKD populations.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Renal Function Panel: A baseline blood test (serum creatinine and eGFR calculation) is absolutely mandatory before prescribing to determine if strict renal dose reductions are required or if the drug is forbidden.
• Cardiovascular Baseline: Strict baseline measurement of your sitting and standing blood pressure and resting heart rate.
• Medication Reconciliation: Your pharmacist must review your chart for other medications that raise blood pressure or heart rate (e.g., over-the-counter decongestants like Sudafed, or certain antidepressants).

Precautions During Treatment

• Timing of Dose: To prevent severe insomnia at night, the medication must be taken first thing in the morning. Do not take it if you plan to go to sleep within the next 9 hours.
• Symptom Vigilance: Monitor yourself for signs of a racing heart, chest pain, or unexplained, intense anxiety.

“Do’s and Don’ts” List

• Do take the medication exactly as prescribed, right after waking up in the morning.
• Do continue using your CPAP machine or dental device every single night if you have Obstructive Sleep Apnea. Sunosi keeps you awake, but it does not fix your breathing.
• Do check your blood pressure regularly at home using a reliable automatic cuff, and keep a written log for your doctor.
• Don’t take a dose late in the morning or in the afternoon if you forget to take it when you wake up. Skip it entirely until the next morning.
• Don’t drink excessive amounts of caffeine (coffee, energy drinks) while taking Sunosi. Mixing caffeine with this drug can severely worsen anxiety, heart rate, and blood pressure spikes.
• Don’t stop taking the medication abruptly if you have been on a high dose for a long time without talking to your doctor. Stopping suddenly can cause extreme, crushing fatigue and “crash” symptoms.

Legal Disclaimer

Standard medical information disclaimer: The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. This content is not intended to be a substitute for professional medical diagnosis, treatment, or clinical judgment. Sunosi is a controlled prescription medication. Always seek the advice of a qualified healthcare provider, neurologist, or sleep specialist regarding a medical condition, treatment options, or before making any changes to your medication regimen. This content reflects clinical and research data available as of 2026.